Vytorin vs. Other Cholesterol Lowering Medications
Links shared publicly online about this topic
Zocor (simvastatin): increased risk of muscle injury with high doses
fda.gov — “Ongoing review shows risk also increased when drug, especially at higher doses, is used with certain drugs.” View full resource at fda.gov
Most Recently Shared on March 19, 2010 at 8:38 pm By:
madan kwatra PhD and Doctor
Zocor (simvastatin): increased risk of muscle injury with high doses: http://bit.ly/dypi2c via @addthis
Ezetimibe and cancer
theheart.org — “Over a four-year period, the rates of cancer-associated adverse events and the proportion of all reported adverse events related to cancer were less than event rates observed with other potent cholesterol-lowering medications.” View full resource at theheart.org
Most Recently Shared on March 25, 2009 at 10:01 pm By:
FDA postmarketing surveillance data show no cancer risk with ezetimibe http://tinyurl.com/cazb7s
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
madan kwatra
Associate Professor, Duke University Medical Center
-
Shelley Wood
Managing editor for heartwire on theheart.org--the most authoritative, balanced, and insightful cardiovascular disease news online. http://is.gd/nHJ4
Advertisement
